Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban

Bibliography

• Schnabel RB, Sullivan LM, Levy D, Developments of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739-45
   PubMed Web of Science ®Google Scholar
• Wolf PA, Benjamin EJ, Belanger AJ. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996;131:790-5
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Heart Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Prins MH, Le Heuzey JY, Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2008;29:1181-9
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon B, Validation of clinical classification schemes for predicting stroke. Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
   PubMed Web of Science ®Google Scholar
• Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31(19):2369-429
   PubMedGoogle Scholar
• Lip GY, Niewlaat R, Pisters R, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 2010;137:263-72
   PubMed Web of Science ®Google Scholar
• Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med 2010;123:484-8
   PubMed Web of Science ®Google Scholar
• Poli D, Lip G, Antonucci E, Stroke risk stratification in a ‘real world’ elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol 23 Jul 2010. [Epub ahead of print]
   Google Scholar
• Brunton LL, Parker LK. Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: Goodman & Gilman's manual of pharmacology and therapeutics. McGraw-Hill; 2008
   Google Scholar
• Hart RG, Pearce LA, Aguilare MI. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in patients taking warfarin. Ann Intern Med 1994;120:897-902
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633-8
   PubMed Web of Science ®Google Scholar
• The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs R, Fletcher K, Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 2007;370:493-503
   PubMed Web of Science ®Google Scholar
• Cios DA, Baker WL, Sander SD, Evaluating the impact of study-level factors on warfarin control in US primary-based studies: a meta-analysis. Am J Health Syst Pharm 2009;66:916-25
   PubMed Web of Science ®Google Scholar
• Hylek EM, Evans-Molina C, Shea C, Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96
   PubMed Web of Science ®Google Scholar
• Poli D, Antonucci E, Grifoni E, Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009;54:999-1002
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaart R, A novel user friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010;18:10-0134
   Google Scholar
• Wu AH. Use of genetic and non-genetic factors in warfarin dosing algorithms. Pharmacogenomics 2007;7:851-61
   Google Scholar
• The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64
   PubMed Web of Science ®Google Scholar
• Bauer LA. Clinical pharmacokinetics and pharmacodynamics concepts. In: Bauer LA, editor, Clinical pharmacokinetcs handbook. McGraw-Hill; 2006. p. 3-18
   Google Scholar
• Chaudhari D, Bhuriya R, Arora R. Newer anticoagulants as alternate to warfarin in atrial fibrillation: a changing paradigm. Am J Ther 10 May 2010 [Epub ahead of print] PMID: 20460986
   Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral venous thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Middledorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40
   PubMed Web of Science ®Google Scholar
• Hauel NH, Nar H, Priepke H, Structure-based design of novel potent non-peptide thrombin inhibitors. J Med Chem 2002;45:1757-66
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European public assessment report: p. Available from: www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-PI-en.pdf [Last accessed 25 May 2010]
   Google Scholar
• Stangier J, Rathgen K, Stahle H, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran, and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007;98:155-62
   PubMed Web of Science ®Google Scholar
• Stangier J, Stahle H, Rathgen K, Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59
   PubMed Web of Science ®Google Scholar
• Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010;103:572-85
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Reilly PA, Nehmiz G, Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-26
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Bleech S, Ebner T, Ludwig-Schwellinger E, The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99
   PubMedGoogle Scholar
• Khoo CW, Lip GYH. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial. Expert Opin Pharmacother 2010;11:685-7
   PubMed Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A, In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct factor Xa inhibitor. Thromb Haemost 2005;3:514-21
   Google Scholar
• European Medicines Agency. CHMP Assessment Report for Xarelto. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_._Public_assessment_report/human/000944/WC500057122.pdf [Last accessed 25 May 2010]
   Google Scholar
• Weinz C, Radtke M, Schmeer K, In vitro metabolism of BAY 59-7939 – an oral, direct factor Xa inhibitor [abstract 195]. Drug Metab Rev 2004;36(Suppl 1):98
   Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Effect of food, an antiacid, and the H2 antagonist ranitidine on the absortion of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-58
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-65
   PubMed Web of Science ®Google Scholar
• Tobu M, Iqbal O, Hoppensteadt D, Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thromb Hemost 2004;10:301-9
   PubMedGoogle Scholar
• Kubitza D, Becka M, Wensing G, Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Voith B, Safety, pharmacodynamics, and pharmacokinetics of single dose of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21
   PubMed Web of Science ®Google Scholar
• The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF Study. Am Heart J 2010;159:340-7
   PubMed Web of Science ®Google Scholar
• Pinto DJ, Orwat MJ, Koch S, Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro 1H-pyrazolo3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-56
   PubMed Web of Science ®Google Scholar
• He K, He B, Grace JE, Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. Available from: www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/910?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=apixaban&searchid=1&FIRSTINDEX=0&volume=108&issue=11&resourcetype=HWCIT [Last accessed 28 February 2010]
   Google Scholar
• Luettgen JM, Bozarth TA, Bozarth JM, In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor [abstract 4130]. Available from: www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/910?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=apixaban&searchid=1&FIRSTINDEX=0&volume=108&issue=11&resourcetype=HWCIT [Last accessed 28 February 2010]
   Google Scholar
• Eikelboom JW, O'Donnell M, Yusuf S, Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heat J 2010;159:348-53
   Google Scholar
• Connolly SJ, Pogue J, Hart RG, Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78
   PubMed Web of Science ®Google Scholar
• AVERROES Study of investigational agent apixaban closes early due to clear evidence of efficacy. Available from: http://www.bms.com/news/press_releases/pages/default.aspx [Last accessed 20 June 2010]
   Google Scholar
• Lopes RD, Alexander JH, Al-Khatib SM, Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-9
   PubMed Web of Science ®Google Scholar
• Oldgren J. Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving clopidogrel. RE-DEEM. Presentad at the American Heart Association Scientific Sessions, 18 November 2009, Orlando, FL, USA. Available from: www.tctmd.com/show.aspx?id=87742 [Last accessed 28 March 2010]
   Google Scholar
• Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010;64(7):956-67
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Dabigatran etexilate versus enoxaparine for prevention of venous thromboembolism after total hip replacement: a randomized, double blind, non-inferiority trial. Lancet 2007;370:949-56
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Oral dabigatran etexilate vs. subcutaneous enoxaparine for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85
   PubMed Web of Science ®Google Scholar
• Ginsberg IS, Davidson BI, Comp PC, Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparine regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
   PubMed Web of Science ®Google Scholar
• Alexander JH, Becker RC, Bhatt DL, Apixaban, an oral direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention Of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-85
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS_TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009;374:29-38
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2010;3:692-4
   Google Scholar
• Van Thiel D, Kalodiki E, Wahi E, interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 mg) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 2009;15:389-94
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, Roivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind, randomized controlled trial. Lancet 2008;372:31-9
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: N Engl J Med 2008;358:1776-86
   Google Scholar
• Turpie AG, Lassen MR, Davidson BL, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. Lancet 2009;373:1673-80
   PubMed Web of Science ®Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM, Efficacy and safety of dabigatran etixilate for the prevention of venous thromboembolism following hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Kakkar JK, Turpie AGG, Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg 2009;91:636-44
   Web of Science ®Google Scholar
• Sylvia H. Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb Haemost 2010;103:686-8
   PubMedGoogle Scholar
• FDA panel supports approval of Pradaxa® (dabigatran etexilate) for stroke reduction in atrial fibrillation. Available from: http://www.nelm.nhs.uk/en/NeLM-Area/News/2010—September/21/FDA-panel-supports-approval-of-Pradaxa-dabigatran-etexilate-for-stroke-reduction-in-atrial-fibrillation/ [Last accessed 23 September 2010]
   Google Scholar
• Schwarz UI, Rithchie MD, Bradford Y, Genetic determinants of response to warfarin during inityial anticoagulation. N Engl J Med 2008;358:999-1008
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Lindh JD, The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92
   PubMed Web of Science ®Google Scholar
• Clarification of Optimal Anticoagulation Through Genetics (COAG) trial. Available from: http://clinicaltrials.gov/ct2/show/NCT00839657 [Last accessed 24 September 2010]
   Google Scholar
• Oake N, Fergusson DA, Forster AJ. Frequency of adverse events in patients with poor anticoagulation: a metaanalysis. Can Med Assoc J 2007;176:1589-94
   PubMed Web of Science ®Google Scholar
• Stangier J, Eriksson BI, Dahl OE, Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy subjects and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-63
   PubMed Web of Science ®Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95
   PubMed Web of Science ®Google Scholar
• Weinz C, Schwarz T, Kubitza D, Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009;37:1056-64
   PubMed Web of Science ®Google Scholar
• Weinz C, Buetehorn U, Daehler HP, Pharmacokinetics of BAY 59-7939 – an oral, direct factor Xa inhibitor – in rats and dogs. Xenobiotica 2005;35:891-910
   PubMed Web of Science ®Google Scholar
• Frost C, Yu Z, Nepal S, Apixaban, a direct factor Xa inhibitor: single dose pharmacokinetics and pharmacodynamics of an intravenous formulations [abstract 142]. J Clin Pharmacol 2008;48:1132
   Web of Science ®Google Scholar
• Raghavan N, Frost CE, Yu Z, Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81
   PubMed Web of Science ®Google Scholar
• Frost C, Yu Z, Moore K, Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost 2007;5(Suppl 2):P-M-664
   Google Scholar
• Wang L, Raghavan N, He K, Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos 2009;37:802-8
   PubMed Web of Science ®Google Scholar